Ann: FDA Grants PharmAust Pre-IND Meeting, page-34

Thanks. Has there been any discussion around any difficulty or delays in enrolling patients for phase 2 when the time comes? I understand from the recent AGM that it could be around 120 patients that may be negotiated with the FDA as part of the phase 2 study.

Also, I think I heard that phase 2 will likely cost around $14m. The CEO has mentioned a number of avenues that are being explored to fund at least some of that without a capital raise. I suppose some risk of a significant dilution if a standard capital raise is required if there isn't much appreciation in the share price hinging on phase 1 result and ODD announcements.